Sorrento Therapeutics Inc (SRNE)

[dia76ca]

"Wonk" found this independant article which highlights Abivirtinib!
"While we are awaiting the abivertinib preliminary results for its phase 2 Covid19 trial, you may find interesting a new study (pre-proof) from European Journal of Pharmacology.
Methodology from the study:
"This paper focuses on identifying inhibitors that target SARS-CoV-2 proteases, PLPRO and 3CLPRO, which control the duplication and manages the life cycle of SARS-CoV-2. We have carried out detailed in silico Virtual high-throughput screening using Food and Drug Administration (FDA) approved drugs from the Zinc database, COVID-19 clinical trial compounds from Pubchem database, Natural compounds from Natural Product Activity and Species Source (NPASS) database and Maybridge database against PLPRO and 3CLPRO proteases."

The authors concluded abivertinib to be a potential top contender to tackle Covid19 based on the screening criteria of the study. Abivertinib was also recommended by the study's authors in their conclusion as a starting point to in the attempt develop Covid19 drug/treatment from existing pharma compounds."

Link to full text:
https://www.sciencedirect.com/science/article/pii/S0014299921002351